Skyclarys approved: HSE to fund Friedreich’s ataxia drug for Irish patients
Decision confirmed ending long-running campaign The HSE’s senior management team said it will reimburse the treatment, which is manufactured by US biotechnology company Biogen and costs €288,000 per patient per year. This comes after the HSE approved funding for Skyclarys, the drug used to treat Friedreich’s ataxia. The decision was confirmed on Tuesday, ending a […]